News

Real-world evidence: Sponsors look to US FDA drug reviews for potential pitfalls

Written by Admin | Oct 7, 2019
Methodological problems with RWE submissions for approved applications may give sponsors ‘a little bit of a pause’ as they work through data selection and analytical issues, Aetion’s Jeremy Rassen says. CDER’s Janet Woodcock says it is easier to use RWE when treatment effects are large.

Read More